MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. GAP
8. DG
9. ULTA
10. NVDA

Go back to MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
(NASDAQ: MBX) Delayed: 63.00 -3.39 (5.11%)
Previous Close $66.39    52 Week High $ 
Open $66.14    52 Week Low $ 
Day High $66.14    P/E N/A 
Day Low $62.99    EPS $ 
Volume 307,655